Characterization of (2R, 3S)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N, 3-dihydroxybutanamide, a potent and selective inhibitor of TNF-α converting enzyme

International Immunopharmacology

Volumn 4, Issue 14 SPEC.ISS., 2004, Pages 1845-1857

  Zhang, Yuhua ^a   Hegen, Martin ^a   Xu, Jun ^b   Keith Jr , James C ^a   Jin, Guixian ^b   Du, Xuemei ^b   Cummons, Terri ^b   Sheppard, Barbara J ^a   Sun, Linhong ^a   Zhu, Yi ^a   Rao, Vikram R ^a   Wang, Qin ^a   Xu, Weixin ^a   Cowling, Rebecca ^b   Nickerson Nutter, Cheryl L ^a   Gibbons, Jay ^b   Skotnicki, Jerry ^b   Lin, Lih Ling ^a   Levin, Jeremy ^b  

^a PFIZER INC   (United States)

^b WYETH RESEARCH   (United States)

Author keywords

Rheumatoid arthritis; Selective TACE inhibitor; TMI 2; TNF

Indexed keywords

2 [[[4 (2 BUTYNYLOXY)PHENYL]SULFONYL]AMINO] N,3 DIHYDROXYBUTANAMIDE; COLLAGEN TYPE 2; GELATINASE B; INTERSTITIAL COLLAGENASE; LIPOPOLYSACCHARIDE; MATRILYSIN; MATRIX METALLOPROTEINASE 14; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL CELL; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 8644242950     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2004.08.003     Document Type: Conference Paper

References (28)

1. M.A. Palladino, F.R. Bahjat, E.A. Theodorakis, and L.L. Moldawer Anti-TNF-alpha therapies: the next generation Nat. Rev., Drug Discov. 2 9 2003 736
2. M. Feldmann, P. Charles, P. Taylor, and R.N. Maini Biological insights from clinical trials with anti-TNF therapy Springer Semin. Immunopathol. 20 1-2 1998 211 228
3. L.W. Moreland, S.W. Baumgartner, M.H. Schiff, E.A. Tindall, R.M. Fleischmann, and A.L. Weaver Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein N. Engl. J. Med. 337 3 1997 141 147
4. M.J. Elliott, R.N. Maini, M. Feldmann, J.R. Kalden, C. Antoni, and J.S. Smolen Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis Lancet 344 8930 1994 1105 1110
5. D.E. Furst, M.H. Schiff, R.M. Fleischmann, V. Strand, C.A. Birbara, and D. Compagnone Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) J. Rheumatol. 30 12 2003 2563
6. R.A. Black, C.T. Rauch, C.J. Kozlosky, J.J. Peschon, J.L. Slack, and M.F. Wolfson A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells Nature 385 1997 729 733
7. M.L. Moss, S.L. Jin, M.E. Milla, D.M. Bickett, W. Burkhart, and H.L. Carter Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha Nature 385 6618 1997 733
8. J.S. Skotnicki, and J.I. Levin TNFa Converting Enzyme (TACE) as a therapeutic target Annu. Rep. Med. Chem. 38 2003 153 162
9. J.S. Skotnicki, M.J. DiGrandi, and J.I. Levin Design strategies for the identification of MMP-13 and Tace inhibitors Curr. Opin. Drug Discov. Dev. 6 5 2003 742
10. Y. Zhang, J. Xu, J. Levin, M. Hegen, G. Li, and H. Robertshaw Identification and characterization of 4-[[4-(2-Butynyloxy)phenyl]sulfonyl]-N- hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-{alpha}-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis J. Pharmacol. Exp. Ther. 309 1 2004 348 355
11. J.I. Levin, J.M. Chen, K. Cheung, D. Cole, C. Crago, and E.D. Santos Acetylenic TACE inhibitors: Part 1. SAR of the acyclic sulfonamide hydroxamates Bioorg. Med. Chem. Lett. 13 16 2003 2799
12. G. Jin, X. Huang, R. Black, M. Wolfson, C. Rauch, and H. McGregor A continuous fluorimetric assay for tumor necrosis factor-alpha converting enzyme Anal. Biochem. 302 2 2002 269 275
13. C. Knight, F. Willenbrock, and G. Murphy A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases FEBS Lett. 296 3 1992 263 266
14. H.A. Harris, L.M. Albert, Y. Leathurby, M.S. Malamas, R.E. Mewshaw, and C.P. Miller Evaluation of an estrogen receptor-beta agonist in animal models of human disease Endocrinology 144 10 2003 4241
15. A.R. Poole, and R.R. Coombs Rheumatoid-like joint lesions in rabbits injected intravenously with bovine serum Int. Arch. Allergy Appl. Immunol. 54 1977 97 113
16. H.J. Mankin, H. Dorfman, L. Lippieo, and L. Zarins Biochemical and metabolic abnormalities in articular cartilage from osteoarthritic human hip J. Bone Jt. Surg. (AM) 53A 1971 152 153
17. J. Branger, B. van den Blink, S. Weijer, J. Madwed, C.L. Bos, and A. Gupta Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia J. Immunol. 168 8 2002 4070
18. K.W. McIntyre, D.J. Shuster, K.M. Gillooly, D.M. Dambach, M.A. Pattoli, and P. Lu A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice Arthritis Rheum. 48 9 2003 2652
19. D. Spina Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease Drugs 63 23 2003 2575
20. S.R. Ruuls, R.M. Hoek, V.N. Ngo, T. McNeil, L.A. Lucian, and M.J. Janatpour Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation Immunity 15 533-543 2001
21. J.T. Peterson Matrix metalloproteinase inhibitor development and the remodeling of drug discovery Heart Fail. Rev. 9 2004 63 79
22. P.E. Dekkers, F.N. Lauw, T. ten Hove, A.A. te Velde, P. Lumley, and D. Becherer The effect of a metalloproteinase inhibitor (GI5402) on tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha receptors during human endotoxemia Blood 94 7 1999 2252 2258
23. J.W. Skiles, N.C. Gonnella, and A.Y. Jeng The design, structure, and therapeutic application of matrix metalloproteinase inhibitors Curr. Med. Chem. 8 2001 425 474
24. R. Renkiewicz, L. Qiu, C. Lesch, X. Sun, R. Devalaraja, and T. Cody Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats Arthritis Rheum. 48 6 2003 1742
25. M.A. Rudek, J. Venitz, and W.D. Figg Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy? Pharmacotherapy 22 6 2002 705 720
26. A.H. Drummond, P. Beckett, P.D. Brown, E.A. Bone, A.H. Davidson, and W.A. Galloway Preclinical and clinical studies of MMP inhibitors in cancer Ann. N.Y. Acad. Sci. 878 1999 228 235
27. M. Grootveld, and M.F. McDermott BMS-561392. Bristol-Myers Squibb Curr. Opin. Investig. Drugs 4 5 2003 598
28. K.G. Vaddi, R.L. Magolda, P.J. Haley, R.J. Collins, T.L. Taylor, and T.P. Maduskuie Characterization of the anti-inflammatory effects of a selective TACE inhibitor, DPC333 Arthritis Rheum. 44 9 2001 S368